STOCK TITAN

Pulse Biosciences (PLSE) director receives grant of 30,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Pulse Biosciences director Manmeet Singh Soni received a grant of stock options, not a share purchase. The award covers 30,000 options to buy Common Stock at an exercise price of $26.89 per share, expiring on June 11, 2036. These options vest in equal monthly installments over one year, starting on July 11, 2026, contingent on continued service, leaving Soni with 30,000 derivative securities after the grant.

Positive

  • None.

Negative

  • None.
Insider Soni Manmeet Singh
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 30,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 30,000 options Grant of Stock Option (right to buy) on June 11, 2026
Exercise price $26.89 per share Exercise price for Common Stock under the option grant
Underlying shares 30,000 shares Common Stock underlying the granted options
Expiration date June 11, 2036 Option term end for the granted stock options
Post-grant derivative holdings 30,000 options Total derivative securities following the transaction
Vesting start date July 11, 2026 First monthly vesting installment for the option grant
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 26.8900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to the option will vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-11T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Soni Manmeet Singh

(Last)(First)(Middle)
C/O PULSE BIOSCIENCES, INC.
3957 POINT EDEN WAY

(Street)
HAYWARD CALIFORNIA 94545

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$26.8906/11/2026A30,000 (1)06/11/2036Common Stock30,000$030,000D
Explanation of Responses:
1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on July 11, 2026.
/s/ Kenneth B. Stratton06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Pulse Biosciences (PLSE) report for Manmeet Singh Soni?

Pulse Biosciences reported that director Manmeet Singh Soni received a grant of 30,000 stock options. These options are a compensation award, not an open-market share purchase or sale, and give the right to buy Common Stock at a fixed exercise price.

How many stock options were granted to the Pulse Biosciences (PLSE) director?

The director received 30,000 stock options. Each option represents the right to buy one share of Pulse Biosciences Common Stock, subject to vesting conditions and an exercise price, providing potential future equity exposure rather than immediate share ownership.

What is the exercise price of the new Pulse Biosciences (PLSE) stock options?

The stock options were granted with an exercise price of $26.89 per share. This means the director can buy Pulse Biosciences Common Stock at $26.89 once the options vest, regardless of the market price at the time of exercise.

When do the new Pulse Biosciences (PLSE) options vest for Manmeet Singh Soni?

The options vest in equal monthly installments over one year, beginning July 11, 2026. Vesting is contingent on the director’s continued service, gradually making more options exercisable each month until the full 30,000 have vested.

When do the granted Pulse Biosciences (PLSE) stock options expire?

The stock options expire on June 11, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase Pulse Biosciences Common Stock, even if they had previously vested.

How many derivative securities does the Pulse Biosciences (PLSE) director hold after this grant?

Following this grant, the director holds 30,000 derivative securities in the form of stock options. This figure reflects the newly awarded options and shows the size of the director’s option-based equity position after the transaction.